Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 142.02% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Citigroup lifted their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research note on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Tuesday. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $9.09 on Tuesday. The company’s 50 day simple moving average is $7.73 and its 200 day simple moving average is $8.72. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analyst estimates of $421.50 million. As a group, equities analysts anticipate that Telix Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in shares of Telix Pharmaceuticals in the third quarter valued at about $1,883,000. Portland Investment Counsel Inc. boosted its position in shares of Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after acquiring an additional 138,200 shares during the period. Lazard Asset Management LLC boosted its position in shares of Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after acquiring an additional 135,893 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $975,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at about $276,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.